Oxford BioMedica takes out $50M loan to service Novartis CAR-T alliance

Nick Paul Taylor Oxford BioMedica has secured a $ 50 million (€45 million) loan, half of which it will take out immediately to expand its laboratory and manufacturing facilities. ...

GW to raise $179M, KDEV’s portfolio value sinks to new low, BIA wants U.K. to rival CA, MA

Nick Paul Taylor In this week's EuroBiotech Report, GW Pharmaceuticals is once again turning to U.S. investors to fuel the advance of its cannabis-based pipeline. The latest offering ...

Ex-Sanofi exec Whitaker lands at Valeant in EVP role

Carly Helfand After departing from Sanofi last year for the CEO's chair at Synta Pharmaceuticals, Anne Whitaker is now moving on to Valeant, where she'll step into the role ...

As patent battle brews, Celgene and GSK lead $64M raise for CRISPR Therapeutics

John Carroll The cascade of venture cash into CRISPR-Cas9 startups is continuing with no end in sight, despite a patent brawl brewing over who owns the technology. Today it's CRISPR ...

Google’s Calico continues its partnering romp on aging R&D with Buck collaboration

John Carroll FierceBiotech News

BMS, focused on immuno-oncology, turns Erbitux over to Eli Lilly

Eric Palmer Erbitux is one of the top 10 best selling cancer drugs in the world and for years Bristol-Myers Squibb has sold it in the U.S. But Erbitux no longer fits in the sweet spot ...

Allergy biotech hauls in $80M for its oral immunotherapy

Damian Garde Food allergy upstart Allergen Research Corporation raised an $ 80 million B round to get its lead candidate into late-stage development, pushing ahead with a treatment ...

Roche neighbors sue, claiming contamination lowered home prices

Carly Helfand Roche handled hazardous chemicals at its now-shuttered facility in Nutley, NJ–and its neighbors say the company didn't do it properly. FiercePharma News

Exclusive: Pfizer is once again cutting back R&D staff in reorganization

John Carroll Pfizer is once again trimming its R&D staff. Responding to a query from FierceBiotech regarding word of cutbacks at research facilities in Cambridge, MA, and Collegeville, ...

Cerecor picks up a Lilly antidepressant with ambitions in addiction

Damian Garde Cerecor acquired the rights to an Eli Lilly antidepressant, planning to take the drug into Phase II as a treatment for addictive disorders.  FierceBiotech News

Valeant closing in on $160-per-share Salix deal: Reuters

Carly Helfand There are reportedly at least three horses in the race to buy Salix Pharmaceuticals, but according to Reuters' sources, serial acquirer Valeant has the lead. FiercePharma ...

Intrexon takes a $60M flyer on a synthetic biology startup

Damian Garde Billionaire R.J. Kirk's Intrexon has signed a $ 60 million deal to acquire ActoGeniX, a Belgian biotech at work on oral drugs designed to generate therapeutic proteins ...
Page 5 of 35« First...34567...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS